Trazimab project funded by Lazio Innova
Prot. A0320-2019-28090 “Progetti Strategici anno 2019”, approved with determination G04052 on date 04/04/2019 in the context of POR FESR LAZIO 2014 – published on BURL n. 29 09/04/2019.
Synthesis of the Project
The project, led by Menarini Biotech, starts from the consideration that the new frontier of the biopharmaceuticals is represented by the ATMP (Advanced Therapy Medicinal Products), including gene and cell therapy. Several start-ups, SMEs and Research Organizations, including hospitals, are involved in this new field in the Regione Lazio. There is a urgent need to increase the standardization of the industrial manufacturing of these new products and a solid background in the GMP manufacturing of biologics is fundamental to drive these therapies into the market. This creates the preconditions for a competitive repositioning of Menarini Biotech into the ATMP field, particularly in the development and industrialization of viral vectors for CAR-T engineering.
Project “TraziMab” will involve Menarini Biotech, Takis Biotech, and OPBG (Ospedale Pediatrico Bambin Gesù) and will deliver an innovative CAR T product for the treatment of Aspergillosis. The proposal will enable partners to benefit from each other and consolidate Lazio as an innovation hub for the Red Biotech, increasing its technological and scientific impacts.
The project is part of the wider group of projects named “IMMUNO”, always co-funded by Lazio Innova and coordinated by OPBG.